• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Monday, September 25, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Oncotarget: CEA as a blood-based biomarker in anal cancer

Bioengineer by Bioengineer
July 14, 2021
in Cancer
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

CEA is not associated with survival outcomes in SCCA, and is not a clinically relevant biomarker in this disease

IMAGE

Credit: Correspondence to – Van K. Morris – [email protected]

Oncotarget published “CEA as a blood-based biomarker in anal cancer” which reported that the mean Carcinoembryonic Antigen (CEA) among subgroups by clinical status at the time of presentation to our institution was highest among those patients with metastatic Squamous cell carcinoma of the anal canal (SCCA) to visceral organs, however this finding was not statistically significant by ANOVA .

By clinical subgroup, the percentage of patients with an abnormally elevated CEA was highest in those patients with metastatic disease to lymph nodes followed by recurrent/unresectable SCCA , and metastatic SCCA to visceral organs, and was statistically significant between groups.

Using RECIST criteria for tumor progression and disease response, the mean change in CEA for patients with progression was an increase in 19 ng/mL, compared to a change of –7.3 ng/mL in those with disease response.

The authors likewise assessed whether CEA levels were associated with survival outcomes for all patients with metastatic SCCA, and found no correlation between CEA and likelihood for survival in a ROC analysis.

Despite interesting patterns of abnormally high CEA in SCCA patients with advanced disease, and correlation of increased CEA with disease progression, CEA is not associated with survival outcomes in SCCA, and is not a clinically relevant biomarker in this disease.

CEA is not associated with survival outcomes in SCCA, and is not a clinically relevant biomarker in this disease

Dr. Van K. Morris from The University of Texas – MD Anderson Cancer Center said, “Squamous cell carcinoma of the anal canal (SCCA) is a rare cancer of the anogenital track with an estimated incidence of about 8500 new cases and 1350 deaths in 2020 in the U.S. annually, comprising 2–3% of all gastrointestinal malignancies.“

Routine, readily available blood-based markers are often utilized in the clinical management of patients with solid tumors across a variety of clinical settings.

For example, trends in biomarkers such as carcinoembryonic antigen, carbohydrate antigen 19-9, prostate-specific antigen and carbohydrate antigen 125 can be monitored serially over time for patents with colorectal cancer, pancreatic cancer, prostate cancer, and ovarian cancer, respectively, as a surrogate for changes in amount of tumor present.

To date, no blood-based biomarker for tracking responses to HPV-associated cancers is readily available to clinical oncologists for routine use.

Among anal cancer patients, one series examined 106 patients with early-stage SCCA treated definitely with chemoradiation and did not find clinical utility in the measurement of CEA in this subset of patients with anal cancer.

Since no blood-based biomarkers are currently available in a CLIA-certified laboratory for the routine management of SCCA, we performed a retrospective, single-institution study to correlate serum CEA levels with clinical and pathologic outcomes in patients across all stages and presentations of SCCA.

The Morris Research Team concluded in their Oncotarget Research Output, “we report the largest series to describe CEA as a serum biomarker for patients with metastatic SCCA. Our findings may not provide definitive support for the use of a routinely used blood-based assay for management of patients with SCCA and should guide clinicians in seeking alternative approaches for tracking responses to treatment in this disease. Nonetheless, novel approaches with serum biomarkers are needed for patients with this rare but increasingly diagnosed malignancy.“

###

DOI – https://doi.org/10.18632/oncotarget.27959

Full text – https://www.oncotarget.com/article/27959/text/

Correspondence to – Van K. Morris – [email protected]

Keywords –
carcinoembryonic antigen,
squamous cell carcinoma of anal canal,
anal cancer,
biomarkers,
HPV

About Oncotarget

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud – https://soundcloud.com/oncotarget
Facebook – Oncotarget/”>https://www.facebook.com/Oncotarget/
Twitter – https://twitter.com/oncotarget
LinkedIn – https://www.linkedin.com/company/oncotarget
Pinterest – https://www.pinterest.com/oncotarget/
Reddit – Oncotarget/”>https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

[email protected]
18009220957×105

Copyright © 2021 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC

Media Contact
Ryan James Jessup
[email protected]

Original Source

https://www.oncotarget.com/news/pr/cea-as-a-blood-based-biomarker-in-anal-cancer/

Related Journal Article

http://dx.doi.org/10.18632/oncotarget.27959

Tags: BiologyBusiness/EconomicscancerCarcinogensEducationMedicine/HealthPolicy/Ethics
Share12Tweet8Share2ShareShareShare2

Related Posts

Baris Borsa, principal research engineer, Linköping University

Researchers pioneer safe chemotherapy methods for treating bacterial infections

September 25, 2023
Dao Nguyen, MD

Sylvester Research: Socioeconomic status linked with outcomes and survival in patients treated for non-small cell lung cancer

September 22, 2023

Louisiana Cancer Research Center Associate Director of Administration Sven Davisson named Treasurer of Association of Independent Research Institutes

September 22, 2023

Australian research leads to clinical trial for rare women’s cancers

September 22, 2023
Please login to join discussion

POPULAR NEWS

  • blank

    Microbe Computers

    58 shares
    Share 23 Tweet 15
  • A pioneering study from Politecnico di Milano sheds light on one of the still poorly understood aspects of cancer

    34 shares
    Share 14 Tweet 9
  • Fossil spines reveal deep sea’s past

    34 shares
    Share 14 Tweet 9
  • Scientists go ‘back to the future,’ create flies with ancient genes to study evolution

    75 shares
    Share 30 Tweet 19

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Researchers pioneer safe chemotherapy methods for treating bacterial infections

ETRI unveiled hyper-realistic technologies for the metaverse world

Global study provides new insights into barriers to effective cardiovascular rehabilitation for women and why women are less likely to participate

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 57 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In